Abcam, ab258601, Human PPP2R5C knockout HEK-293T cell lysate

Size: 1Kit
PPP2R5C KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp deletion in exon 1.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp deletion in exon 1.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-PPP2R5C, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The protein phosphatase 2 regulatory subunit B' gamma also known as PPP2R5C is a regulatory component of the protein phosphatase 2A (PP2A) holoenzyme. PPP2R5C has a molecular weight of approximately 59 kDa. This protein shows expression in various tissues including brain kidney spleen and liver. PPP2R5C serves as a modulator by altering the substrate selectivity or catalytic activity of the PP2A core enzyme which consists of a catalytic subunit and a structural subunit.
Biological function summary
The protein plays a role in mediating cellular processes through its participation as part of the PP2A holoenzyme complex. PP2A regulates various cellular activities including cell cycle progression apoptosis and signal transduction. PPP2R5C contributes to these biological processes by modulating enzyme activity and directing the PP2A holoenzyme to specific subcellular compartments or substrates. This makes PPP2R5C essential for maintaining cellular homeostasis and response to environmental signals.
Pathways
PPP2R5C functions in key signaling pathways such as the MAPK/ERK pathway and the PI3K/AKT pathway. In the MAPK/ERK pathway PPP2R5C affects phosphorylation states and downstream signaling outcomes. The protein also interacts with other components such as AKT enabling regulation of cellular growth metabolism and survival mechanisms. These interactions define the influence of PPP2R5C on signal propagation and impact the overall cellular response.
Alterations in PPP2R5C have been implicated in cancer and neurodegenerative diseases. In cancer abnormal PP2A activity linked with PPP2R5C affects cell cycle regulation and tumorigenesis interacting with cancer-related pathways and proteins like MYC. In neurodegenerative diseases dysfunctions in signaling mechanisms where PPP2R5C is involved contribute to disease progression affecting proteins related to neuron survival and function. Understanding the role of PPP2R5C in these diseases provides insight into potential therapeutic targets.